Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 16/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.48 |
| ▸ | AKT1 | P31749 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | MARK3 | P27448 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.48 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.48 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.48 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726072 | 0.90 | TGFBR1 (0.48) | TGFBR1RPS6KA3AKT1AURKACDK1 | |
| SCHEMBL27997668 | 0.80 | AURKA (0.50) | RPS6KA3AURKAFGFR1PRKACAPRKCD | |
| SCHEMBL6070097 | 0.77 | TGFBR1 (0.60) | TGFBR1RPS6KA3AKT1AURKACDK1 | |
| SCHEMBL5726693 | 0.77 | MAPK14 (0.50) | TGFBR1RPS6KA3PRKACAGSK3BMAPK14 | |
| SCHEMBL6070542 | 0.75 | TGFBR1 (0.55) | TGFBR1RPS6KA3AKT1AURKACDK1 | |
| SCHEMBL6070023 | 0.75 | TGFBR1 (0.32) | TGFBR1PRKCDMAPK14 | |
| SCHEMBL6069875 | 0.71 | TGFBR1 (0.52) | TGFBR1CDK2GSK3BPRKCD | |
| SCHEMBL27618478 | 0.71 | MAPK8 (0.52) | AKT1AURKAPIM1AKT2 | |
| SCHEMBL5248907 | 0.69 | RPS6KA3 (0.81) | TGFBR1RPS6KA3AKT1AURKACDK1 | |
| Bromide SCHEMBL11756541 | 0.68 | RPS6KA3 (0.79) | TGFBR1RPS6KA3AKT1AURKACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109204-B2 | controlling signal transduction; anticancer agents, antitumor agents, atherosclerosis, vision defects, antidiabetic agents, antiinflammatory agents | MERCK & CO., INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | disclosed |
| WO-2003011837-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | FLT4, KDR, FLT1 | TGFBR1 429/4885RPS6KA3 268/4885AKT1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.